Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.46 USD | +2.10% | +4.29% | -0.68% |
03-13 | Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 | |
03-13 | Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Business Summary
Number of employees: 46
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Treatments for Multi-drug Resistant Bacterial Infections
100.0
%
| 54 | 100.0 % | 104 | 100.0 % | +93.95% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 54 | 100.0 % | 104 | 100.0 % | +93.95% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Satyavrat Shukla
CEO | Chief Executive Officer | 52 | 21-01-03 |
Ankit Mahadevia
FOU | Founder | 43 | 13-03-31 |
Esther Rajavelu
DFI | Director of Finance/CFO | 46 | 11-05 |
Kamal Hamed
CTO | Chief Tech/Sci/R&D Officer | 63 | 22-09-14 |
Angela Talley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Timothy Keutzer
COO | Chief Operating Officer | 56 | - |
Ted Jenkins
IRC | Investor Relations Contact | - | - |
James P. Brady
HRO | Human Resources Officer | - | - |
Ian A. Critchley
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Frank Thomas
BRD | Director/Board Member | 54 | 17-06-30 |
John Pottage
BRD | Director/Board Member | 71 | 18-08-13 |
Scott Jackson
BRD | Director/Board Member | 60 | 20-04-15 |
Milind Deshpande
FOU | Founder | 68 | 13-12-31 |
Director/Board Member | 61 | 15-08-31 | |
Ankit Mahadevia
FOU | Founder | 43 | 13-03-31 |
Cynthia Smith
BRD | Director/Board Member | 55 | 19-03-18 |
Director/Board Member | 53 | 21-10-10 | |
Satyavrat Shukla
CEO | Chief Executive Officer | 52 | 21-01-03 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 53,892,889 | 42,916,769 ( 79.63 %) | 0 | 79.63 % |
Company contact information
Spero Therapeutics, Inc.
675 Massachusetts Avenue 14th floor
02139, Cambridge
+857 242 1600
http://www.sperotherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.68% | 78.68M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- SPRO Stock
- Company Spero Therapeutics, Inc.